Y-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%

1d ago, source:

After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.

YMAB Y-mAbs Therapeutics, Inc.

2d ago, source: Seeking Alpha

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the ...

New Strong Buy Stocks for April 19th

Opinion ago, source: Zacks.com on MSN

List today: Trip.com Group Limited TCOM: This travel service provider has seen the Zacks Consensus Estimate for its current ...

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

1mon ago, source: Nasdaq

NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development ...

Y-mAbs Therapeutics Inc.

2d ago, source: Wall Street Journal

1 Day YMAB 1.54% DJIA 0.17% Russell 2K -0.42% Health Care/Life Sciences -0.37% ...

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer

1mon ago, source: Stockhouse

NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical ...

Y-mAbs Therapeutics Inc

25d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Y-mAbs Therapeutics Inc.

22d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...